Aceso Life Science Group Limited reported earnings results for the full year ended March 31, 2022. For the full year, the company reported sales was HKD 315 million compared to HKD 346 million a year ago. Net loss was HKD 370 million compared to HKD 376 million a year ago. Basic loss per share from continuing operations was HKD 0.0514 compared to HKD 0.0573 a year ago. Diluted loss per share from continuing operations was HKD 0.0555 compared to HKD 0.0633 a year ago.